Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H16N4O7S |
| Molecular Weight | 324.311 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCONC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
InChI
InChIKey=RSBPYSTVZQAADE-RQJHMYQMSA-N
InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
| Molecular Formula | C9H16N4O7S |
| Molecular Weight | 324.311 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nacubactam (FPI-1459) was developed as an antibacterial drug. Nacubactam successfully has completed phase I clinical trials for the treatment of serious gram-negative bacterial infections. The drug is currently being developed for the treatment of complicated urinary tract infection, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infections. FPI-1459 works through several mechanisms of action, inhibiting a number of beta-lactamase enzymes as well as certain bacterial cell wall enzymes. In January 2019, FPI-1459 received Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration (FDA).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2725 Sources: http://aac.asm.org/content/60/1/554 |
10.0 nM [IC50] |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:38:16 GMT 2023
by
admin
on
Sat Dec 16 11:38:16 GMT 2023
|
| Record UNII |
832O37V7MZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1452458-86-4
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
73386748
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
832O37V7MZ
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
EF-79
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
DB15353
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
100000174644
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
10300
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY | |||
|
C175153
Created by
admin on Sat Dec 16 11:38:16 GMT 2023 , Edited by admin on Sat Dec 16 11:38:16 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SOLVATE->ANHYDROUS |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
A diazabicyclooctane beta-lactamase inhibitor, for treating bacterial infection. In July 2016, nacubactam was reported to be in phase 1 clinical development.
Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester
A .BETA.-lactamase inhibitor potentially for the treatment of bacterial infections.
|
